We are live on
!
Find out more
RCM
RA Capital Management Portfolio holdings
AUM
$11.5B
1-Year Est. Return
168.77%
This Fund
S&P 500
This Quarter
Est. Return
-17.8%
1 Year Est. Return
+168.77%
3 Year Est. Return
+596.08%
5 Year Est. Return
+846.46%
10 Year Est. Return
+54,223.74%
AUM
$4.58B
AUM Growth
-$1.09B
(-19%)
Cap. Flow
+$290M
Cap. Flow
% of AUM
6.34%
Top 10 Holdings %
Top 10 Hldgs %
44.83%
Holding
107
New
10
Increased
11
Reduced
7
Closed
11
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Biogen
BIIB
|
+$158M |
| 2 |
Natera
NTRA
|
+$78.7M |
| 3 |
Enanta Pharmaceuticals
ENTA
|
+$62.7M |
| 4 |
AN2 Therapeutics
ANTX
|
+$55.6M |
| 5 |
Cytek Biosciences
CTKB
|
+$51M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Novavax
NVAX
|
+$125M |
| 2 |
Phathom Pharmaceuticals
PHAT
|
+$61.3M |
| 3 |
ZGNX
Zogenix, Inc.
ZGNX
|
+$54.2M |
| 4 |
C4 Therapeutics
CCCC
|
+$44.4M |
| 5 |
TG Therapeutics
TGTX
|
+$42M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 98.82% |
| 2 | Financials | 0.96% |
| 3 | Miscellaneous | 0.22% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Ascendis Pharma A/S
ASND
$15.8B
| $888M | 19.38% |
7,567,900
| – | – |
|
|
2
Biogen
BIIB
$31.9B
| $153M | 3.34% |
+727,024
| New | +$158M |
|
|
JBIO
3
Jade Biosciences
JBIO
$1.11B
| $151M | 3.31% |
236,114
| – | – |
|
|
4
Cytek Biosciences
CTKB
$636M
| $144M | 3.15% |
13,381,054
+3,774,026
| +39% | +$51M |
|
|
ITOS
5
DELISTED
iTeos Therapeutics
ITOS
| $142M | 3.1% |
4,417,259
| – | – |
|
6
Travere Therapeutics
TVTX
$5.89B
| $127M | 2.77% |
4,922,941
-691,487
| -12% | -$18.4M |
|
7
Janux Therapeutics
JANX
$1.01B
| $124M | 2.71% |
8,670,644
| – | – |
|
8
Vaxcyte
PCVX
$8.81B
| $111M | 2.41% |
4,581,203
+340,739
| +8% | +$7.44M |
|
|
CLYM
9
Climb Bio
CLYM
$799M
| $110M | 2.41% |
13,150,849
| – | – |
|
|
IMGN
10
DELISTED
Immunogen Inc
IMGN
| $103M | 2.26% |
21,741,458
+1,500,000
| +7% | +$8.3M |
|
|
DICE
11
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
| $99.6M | 2.17% |
5,208,911
| – | – |
|
12
GH Research
GHRS
$1.89B
| $88.3M | 1.93% |
4,827,330
+1,983,573
| +70% | +$35M |
|
|
FMTX
13
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
| $83.8M | 1.83% |
9,011,651
| – | – |
|
14
Tyra Biosciences
TYRA
$1.52B
| $77.4M | 1.69% |
7,236,454
| – | – |
|
|
PNT
15
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
| $71.8M | 1.57% |
9,003,018
| – | – |
|
16
Celldex Therapeutics
CLDX
$3.02B
| $70.7M | 1.54% |
2,075,000
+270,205
| +15% | +$8.64M |
|
|
BLU
17
DELISTED
BELLUS Health Inc.
BLU
| $70.4M | 1.54% |
10,230,274
| – | – |
|
|
18
Enanta Pharmaceuticals
ENTA
$358M
| $68.6M | 1.5% |
+964,212
| New | +$62.7M |
|
19
Vor Biopharma
VOR
$1.32B
| $67.2M | 1.47% |
556,049
| – | – |
|
20
Nkarta
NKTX
$206M
| $63.8M | 1.39% |
5,605,129
| – | – |
|
|
MRTX
21
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $60.4M | 1.32% |
734,343
+353,297
| +93% | +$36.1M |
|
|
DAWN
22
DELISTED
Day One Biopharmaceuticals
DAWN
| $60.1M | 1.31% |
6,060,090
+1,094,502
| +22% | +$14.5M |
|
23
Rhythm Pharmaceuticals
RYTM
$6.66B
| $56.1M | 1.22% |
4,871,067
| – | – |
|
|
24
AN2 Therapeutics
ANTX
$202M
| $55.3M | 1.21% |
+3,666,663
| New | +$55.6M |
|
25
Relmada Therapeutics
RLMD
$474M
| $54M | 1.18% |
2,000,000
| – | – |
|
Similar funds
AAIS
MG
CC
AI
BMSSC
HTC
WAM
RA Capital Management's Q1 2022 Portfolio in Review
As of Q1 2022, RA Capital Management held 107 positions worth $4.58B, down 19% from $5.67B the previous quarter. Its ten largest holdings account for 45% of the portfolio.
RA Capital Management deployed $290M of net new capital in Q1 2022, opening 10 new positions and adding to 11 existing holdings. Its largest new stake was Biogen: 727,024 shares worth $153M.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Financials and Miscellaneous.
On the sell side, the largest reduction was Novavax, an estimated $125M trimmed.
- RA Capital Management's largest Q1 2022 buy was Biogen: 727,024 shares worth $153M.
- RA Capital Management added most to Cytek Biosciences in Q1 2022, an estimated $51M increase.
- RA Capital Management's biggest Q1 2022 reduction was Novavax, cutting an estimated $125M.
- RA Capital Management fully exited Phathom Pharmaceuticals in Q1 2022, selling an estimated $61.3M.
- RA Capital Management's ten largest holdings make up 45% of its $4.58B portfolio in Q1 2022.
- RA Capital Management opened 10 new positions and closed 11 in Q1 2022.
- RA Capital Management's portfolio value fell 19% quarter-over-quarter to $4.58B.
Based on RA Capital Management's 13F filing for Q1 2022, filed 16 May 2022.